Disease | hyperprolactinemia |
Comorbidity | C0001430|adenoma |
Sentences | 3 |
PubMedID- 20963563 | Patients were divided into three groups according to treatment outcomes and pathologic results: (a) prolactinoma that responded to dopamine agonist (da) treatment (prda); (b) prolactinoma requiring surgical treatment (prs); and (c) non-functioning pituitary adenoma with hyperprolactinemia (nfpah). |
PubMedID- 22418404 | hyperprolactinemia in a patient with a pituitary adenoma receiving antipsychotic drug therapy. |
PubMedID- 22838183 | Pathological hyperprolactinemia may result from a lactotroph adenoma (prolactinoma), empty sella syndrome, intracranial tumors compressing the pituitary stalk or hypothalamus, dopamine receptor d2 antagonist and prl stimulative drugs, repetitive mechanical stimulation of breast, chest wall trauma, hepatorenal disease and primary hypothyroidism (4–6). |
Page: 1